Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

Benzinga · 03/21 10:53
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.